The collaboration is designed to create new opportunities to further improve the efficacy of several of Merial’s new vaccine development targets.
In Cell Art claims that the ICA614 nanocarrier, a DNA synthetic formulation, offers efficient and industrial features such as the dramatic enhancement of the immunogenicity of plasmid DNA-encoding tumours or pathogen-derived antigens, a reduction in the dose of plasmid DNA, as well as an excellent safety profile.
ICA614 represents an important step in DNA vaccine development, and is currently being either used or tested by major vaccine companies. In Cell Art has demonstrated that the ICA614 nanocarrier can increase the immunogenicity of sub-unit vaccines containing recombinant proteins.
In Cell Art CEO Chloe Bellocq and co-founder and scientific advisor Bruno Pitard said that In Cell Art was pleased to enter into the collaboration agreement with Merial.
"This agreement highlights In Cell Art’s nanocarrier technology for new vaccine development," Bellocq and Pitard said.